PM360

NOVEMBER 29, 2022

When developing content for new drug labels, life sciences companies’ regulatory teams face challenges in gathering intelligence to better understand competitive factors, market dynamics, and effective approval strategies. Understanding patient sub-group exceptions for competitive or for label development purposes.

Food and Drug Administration 98

Food and Drug Administration Competition Safety Pharmacology 98

Quantified

JUNE 28, 2022

On the one hand, patient need for access and business need to restore and accelerate sales and prescription momentum have never been more critical. The challenge is that with the broad adoption of this approach, it is now table stakes—a must-do rather than a competitive advantage.

Sales 52

Sales Pharma Training Management 52

Pharmaceutical Technology

MARCH 16, 2023

However, health specialists refute most safety concerns for the use of drug classes as part of gender affirming care, citing years of research and care. With restricted access and reduced prescription of puberty blockers and hormone therapies, the impact on pharmaceutical companies manufacturing these therapies also remains unclear.

Ethics 144

Ethics Prescription Safety Healthcare 144